Li Hui-Fang, Meng Wen-Tong, Jia Yong-Qian, Jiang Neng-Gang, Zeng Ting-Ting, Jin Yong-Mei, Huang Qiao-Rong, Li Xue, Xu Hong, Mo Xian-Ming
Laboratory of Stem Cell Biology, State Key Laboratory of Biotherapy Department of Hematology Department of Laboratory Medicine, West China Hospital Collaborative Innovation Center for Biotherapy, Sichuan University, Chengdu, China.
Medicine (Baltimore). 2016 Aug;95(34):e4128. doi: 10.1097/MD.0000000000004128.
B cell acute lymphoblastic leukemia (B-ALL) exhibits phenotypes reminiscent of normal stages of B-cell development. As demonstrated by flow cytometry, the immunophenotypes are able to determine the stages of B cell development. Multicolor flow cytometry (MFC) is more accurate at identifying cell populations. In this study, 9-color panels, including CD10, CD19, CD20, CD22, CD34, CD79a, CD179a, and IgM, which are sequentially expressed during B cell development, were designed to detect the leukemia cell subpopulations in adult B-ALL patients. In 23 patients at diagnosis, 192 heterogeneous subpopulations of leukemia cells were detected. Compared with their counterparts at diagnosis and after the 1st course of induction therapy, the responses of the subpopulations were also heterogeneous. In the CD10 population, the residual B cell subpopulations in the BCR/ABL patients were obviously reduced compared to those in the BCR/ABL patients. New subpopulations were detected in 22 of 23 patients and were primarily located in the CD34CD10 populations. Subpopulations of clonal evolution were heterogeneous after induction therapy. Our results suggest that the subpopulations in B-ALL patients should be dynamically monitored by development-associated immunophenotyping before, during, and after induction therapy and to predict the prognosis of the disease.
B 细胞急性淋巴细胞白血病(B-ALL)表现出类似于 B 细胞发育正常阶段的表型。流式细胞术显示,免疫表型能够确定 B 细胞发育阶段。多色流式细胞术(MFC)在识别细胞群体方面更为准确。在本研究中,设计了包含 CD10、CD19、CD20、CD22、CD34、CD79a、CD179a 和 IgM 的 9 色面板,这些标志物在 B 细胞发育过程中依次表达,用于检测成人 B-ALL 患者的白血病细胞亚群。在 23 例诊断患者中,检测到 192 个异质性白血病细胞亚群。与诊断时及第 1 疗程诱导治疗后的对应亚群相比,这些亚群的反应也是异质性的。在 CD10 群体中,BCR/ABL 患者的残留 B 细胞亚群明显少于非 BCR/ABL 患者。在 23 例患者中的 22 例检测到新的亚群,主要位于 CD34CD10 群体中。诱导治疗后克隆进化的亚群是异质性的。我们的结果表明,应在诱导治疗前、治疗期间和治疗后通过与发育相关的免疫表型分析对 B-ALL 患者的亚群进行动态监测,以预测疾病的预后。